Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology

ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata Significant progress made in advancing the Alys pipeline following $100m seed financing from Medicxi BOSTON and LAUSANNE, Switzerland, Feb. 4, 2025 /PRNewswire/ — Alys Pharmaceuticals,…